The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective randomized phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) patients (pts) with nonsquamous (non SCC) histologic type: NAVoTRIAL01—Preliminary results.
Jaafar Bennouna
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Roche
Petr Zatloukal
No relevant relationships to disclose
Maciej Jerzy Krzakowski
No relevant relationships to disclose
Jens Kollmeier
Consultant or Advisory Role - Boehringer Ingelheim (U); Lilly (U); Roche (U)
Alain Riviere
No relevant relationships to disclose
Eric Dansin
No relevant relationships to disclose
Monika Serke
Employment or Leadership Position - Lungenklinik Hemer
Consultant or Advisory Role - Fa Lilly
Honoraria - Fa Lilly
Adolfo G. Favaretto
No relevant relationships to disclose
Libor Havel
No relevant relationships to disclose
Stephanie Malasse
Employment or Leadership Position - Pierre Fabre Medicament
Fabienne Biville-Hedouin
Employment or Leadership Position - Pierre Fabre Medicament
Eng Huat Tan
No relevant relationships to disclose